2026 Interim report
Filed with HKEX · Stock code 2335 · · 82 pages · English and Chinese
Summary by 6ix AI
The report highlights significant losses attributed to increased research and development expenses, alongside a notable turnaround in cash flow from operating activities. Additionally, the company has made progress in clinical trials for its core product and other candidates, securing important regulatory recognitions and partnerships. The report also outlines the company's strategic focus on developing bi-/multi-specific peptide drugs for treating metabolic and cardiovascular diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shaanxi Micot Pharmaceutical Technology Co., Ltd. on 6ix
Earlier from Shaanxi Micot Pharmaceutical Technology
- Announcement of allotment results
- List of directors and their roles and functions
- Documents on Display
Later from Shaanxi Micot Pharmaceutical Technology
- Notification letter to non-registered shareholders and reply form
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Proposed adoption of the h share incentive scheme and proposed general mandate to repurchase h shares
- Proposed general mandate to repurchase h shares and notice of extraordinary general meeting
- Notice of extraordinary general meeting
Follow Shaanxi Micot Pharmaceutical Technology into a list and get an email when it puts out news.
Follow Shaanxi Micot Pharmaceutical Technology